
## José Palacios

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5616680/publications.pdf Version: 2024-02-01



Ιοςà Ο Ρλιλείος

#	Article	IF	CITATIONS
1	RNA SARS-CoV-2 Persistence in the Lung of Severe COVID-19 Patients: A Case Series of Autopsies. Frontiers in Microbiology, 2022, 13, 824967.	3.5	18
2	Differences in the Molecular Profile between Primary Breast Carcinomas and Their Cutaneous Metastases. Cancers, 2022, 14, 1151.	3.7	5
3	Neuropathological findings in fatal COVID-19 and their associated neurological clinical manifestations. Pathology, 2022, 54, 738-745.	0.6	12
4	Molecular Heterogeneity of High Grade Colorectal Adenocarcinoma. Cancers, 2021, 13, 233.	3.7	4
5	Pulmonary vascular proliferation in patients with severe COVID-19: an autopsy study. Thorax, 2021, 76, 1044-1046.	5.6	12
6	Secondary haemophagocytic lymphohistiocytosis in COVID-19: correlation of the autopsy findings of bone marrow haemophagocytosis with HScore. Journal of Clinical Pathology, 2021, , jclinpath-2020-207337.	2.0	18
7	Epithelial Mesenchymal Transition and Immune Response in Metaplastic Breast Carcinoma. International Journal of Molecular Sciences, 2021, 22, 7398.	4.1	13
8	Clinical, Pathological, and Molecular Features of Breast Carcinoma Cutaneous Metastasis. Cancers, 2021, 13, 5416.	3.7	7
9	Immuneâ€related gene expression signatures: a step forward in the stratification of patients with ovarian clear cell carcinoma â€. Journal of Pathology, 2021, , .	4.5	Ο
10	The Frequency and Prognostic Significance of the Histologic Type in Early-stage Ovarian Carcinoma. American Journal of Surgical Pathology, 2020, 44, 149-161.	3.7	21
11	Mutational Screening of BRCA1/2 Genes as a Predictive Factor for Therapeutic Response in Epithelial Ovarian Cancer: A Consensus Guide from the Spanish Society of Pathology (SEAP-IAP) and the Spanish Society of Human Genetics (AEGH). Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 195-207.	2.8	12
12	Molecular Features of Metaplastic Breast Carcinoma: An Infrequent Subtype of Triple Negative Breast Carcinoma. Cancers, 2020, 12, 1832.	3.7	30
13	Next generation sequencing to decipher concurrent loss of PMS2 and MSH6 in colorectal cancer. Diagnostic Pathology, 2020, 15, 84.	2.0	3
14	Morphological and molecular heterogeneity of epithelial ovarian cancer: Therapeutic implications. European Journal of Cancer, Supplement, 2020, 15, 1-15.	2.2	15
15	Mismatch Repair Deficiency in Ovarian Carcinoma. American Journal of Surgical Pathology, 2020, 44, 649-656.	3.7	44
16	Molecular Basis of Tumor Heterogeneity in Endometrial Carcinosarcoma. Cancers, 2019, 11, 964.	3.7	54
17	High Frequency of ERBB2 Activating Mutations in Invasive Lobular Breast Carcinoma with Pleomorphic Features. Cancers, 2019, 11, 74.	3.7	33
18	Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clinical and Translational Oncology, 2018, 20, 274-285.	2.4	5

JOSé PALACIOS

#	Article	IF	CITATIONS
19	Modified SureSelectQXT Target Enrichment Protocol for Illumina Multiplexed Sequencing of FFPE Samples. Biological Procedures Online, 2018, 20, 19.	2.9	4
20	Pleomorphic lobular carcinoma of the breast with osteoclast-like giant cells: a case report and review of the literature. Diagnostic Pathology, 2018, 13, 62.	2.0	11
21	Dose-Response Association of CD8 <sup>+</sup> Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncology, 2017, 3, e173290.	7.1	260
22	Molecular genetic heterogeneity in undifferentiated endometrial carcinomas. Modern Pathology, 2016, 29, 1390-1398.	5.5	80
23	Loss of the tumor suppressor spinophilin (PPP1R9B) increases the cancer stem cell population in breast tumors. Oncogene, 2016, 35, 2777-2788.	5.9	31
24	Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer. Oncotarget, 2016, 7, 56295-56308.	1.8	83
25	Nuclear TAZ expression associates with the triple-negative phenotype in breast cancer. Endocrine-Related Cancer, 2015, 22, 443-454.	3.1	66
26	A role for the transducer of the Hippo pathway, TAZ, in the development of aggressive types of endometrial cancer. Modern Pathology, 2015, 28, 1492-1503.	5.5	23
27	Zeb1 and <scp>S</scp> nail1 engage mi <scp>R</scp> â€200f transcriptional and epigenetic regulation during <scp>EMT</scp> . International Journal of Cancer, 2015, 136, E62-73.	5.1	52
28	Prognostic relevance of estrogen receptor-α Ser167 phosphorylation in stage II-III colon cancer patients. Human Pathology, 2014, 45, 2437-2446.	2.0	13
29	A core microRNA signature associated with inducers of the epithelial-to-mesenchymal transition. Journal of Pathology, 2014, 232, 319-329.	4.5	66
30	VGLL1 expression is associated with a triple-negative basal-like phenotype in breast cancer. Endocrine-Related Cancer, 2014, 21, 587-599.	3.1	53
31	Molecular events in endometrial carcinosarcomas and the role of high mobility group AT-hook 2 in endometrial carcinogenesis. Human Pathology, 2013, 44, 244-254.	2.0	30
32	ZEB1 overexpression associated with E-cadherin and microRNA-200 downregulation is characteristic of undifferentiated endometrial carcinoma. Modern Pathology, 2013, 26, 1514-1524.	5.5	68
33	Lobular Neoplasia of the Breast Revisited With Emphasis on the Role of E-Cadherin Immunohistochemistry. American Journal of Surgical Pathology, 2013, 37, e1-e11.	3.7	137
34	Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer. Annals of Oncology, 2012, 23, 625-631.	1.2	106
35	MicroRNA-200 Family Modulation in Distinct Breast Cancer Phenotypes. PLoS ONE, 2012, 7, e47709.	2.5	85
36	Genomic and mutational profiling of ductal carcinomas <i>in situ</i> and matched adjacent invasive breast cancers reveals intraâ€ŧumour genetic heterogeneity and clonal selection. Journal of Pathology, 2012, 227, 42-52.	4.5	138

José Palacios

#	Article	IF	CITATIONS
37	Microâ€RNA signature of the epithelial–mesenchymal transition in endometrial carcinosarcoma. Journal of Pathology, 2011, 223, 72-80.	4.5	194
38	Functional characterization of E- and P-cadherin in invasive breast cancer cells. BMC Cancer, 2009, 9, 74.	2.6	61
39	The morphological and molecular features of the epithelial-to-mesenchymal transition. Nature Protocols, 2009, 4, 1591-1613.	12.0	185
40	Pathogenetic Pathways in Ovarian Endometrioid Adenocarcinoma. American Journal of Surgical Pathology, 2009, 33, 1157-1163.	3.7	72
41	Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas. Journal of Pathology, 2008, 215, 231-244.	4.5	153
42	Epithelial-Mesenchymal Transition in Breast Cancer Relates to the Basal-like Phenotype. Cancer Research, 2008, 68, 989-997.	0.9	934
43	Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas. Human Pathology, 2006, 37, 1042-1049.	2.0	69
44	Genetic Profiling of Epithelial Cells Expressing E-Cadherin Repressors Reveals a Distinct Role for Snail, Slug, and E47 Factors in Epithelial-Mesenchymal Transition. Cancer Research, 2006, 66, 9543-9556.	0.9	285
45	Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. Journal of Pathology, 2005, 207, 1-13.	4.5	172
46	Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. Oncogene, 2004, 23, 3272-3283.	5.9	185
47	Epigenetic and genetic alterations of <i>APC</i> and <i>CDH1</i> genes in lobular breast cancer: Relationships with abnormal Eâ€cadherin and catenin expression and microsatellite instability. International Journal of Cancer, 2003, 106, 208-215.	5.1	186
48	Frequent E-cadherin Gene Inactivation by Loss of Heterozygosity in Pleomorphic Lobular Carcinoma of the Breast. Modern Pathology, 2003, 16, 674-678.	5.5	81
49	β-Catenin Expression Pattern, β-Catenin Gene Mutations, and Microsatellite Instability in Endometrioid Ovarian Carcinomas and Synchronous Endometrial Carcinomas. Diagnostic Molecular Pathology, 2001, 10, 116-122.	2.1	138
50	Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors. Cancer, 2001, 92, 2829-2836.	4.1	103
51	The Prognostic Significance of P-Cadherin in Infiltrating Ductal Breast Carcinoma. Modern Pathology, 2001, 14, 650-654.	5.5	85
52	β-Catenin expression pattern in primary oesophageal squamous cell carcinoma. Relationship with clinicopathologic features and clinical outcome. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2000, 437, 599-604.	2.8	41
53	E-cadherin expression in basal cell carcinoma. British Journal of Cancer, 1994, 69, 157-162.	6.4	65
54	Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. American Journal of Pathology, 1993, 142, 987-93.	3.8	288

#	Article	IF	CITATIONS
55	Apical mitochondria-rich cells in the human epididymis: An ultrastructural, enzymohistochemical, and immunohistochemical study. The Anatomical Record, 1991, 231, 82-88.	1.8	33